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Abstract 
The aim of this study is to select among potential tumor models that could be suitable to follow the 
metastatic spead of tumor cells. 18FDG-PET tumor diagnostic test has been adapted to investigate 
tumor growth in vivo in local and metastatic rat models. Materials and Methods. The expression 
of glucose transporters was traced by immunohistological analysis, followed by the uptake of 
18FDG and visualized by MiniPET scanner. After s.c. administration of hepatocarcinoma (He/De) 
cells intensive local tumor growth and 18FDG uptake were measured. Results: Whole body 
18FDG-PET imaging supported by histological analysis have shown that subcutaneously growing 
tumors did not project metastases to other sites from the injected area. To avoid local tumor 
formation i.v. injection was chosen, but did not improve the safety of tumor cell administration. 
Tumor formation after i.v. injection took a longer time than after s.c. administration. Tumors upon 
i.v. generation were smaller and detectable in liver and lung, but not in other organs or tissues. iii) 
Subrenally implanted He/De cells spread from the retroperitoneal primary tumor of the kidney to 
thoracal paratymic lymph nodes (PTNs). The spread from primary site to metastatic tumors in 
PTNs was confirmed by post mortem surgery and histological examinations. Conclusion: Among 
the three methods applied: a) Local s.c. administration of tumor cells generated local tumors 
unsuitable to study metastasis. b) Intravenous administration causing unpredicatable location of 
tumor formation is not regarded a reliable metastatic tumor model. c) Subreanal implantation 
model proved to be a suitable model to follow the metastatic process in rats. 
Key words: transplantation, metastatic models, tumor diagnostics, subrenal capsule model, mini-
PET, immunohistochemistry. 
Introduction 
There are different ways to introduce tumor cells 
in experimental animals. One of the major groups of 
transplantations is represented by those methods that 
place tumor cells in tissues of rodents. Among these 
methods are local subcutaneous (s.c.), intradermal 
(i.d.) and intramuscular (i.m.) injections. Local im-
plantations may or may not generate metastasis. 
Based on the seed and soil hypothesis the orthotopic 
implantation of tumors to the same tissue of host 
mice, it would be expected that  they mimicked more 
closely human tumor development [1]. Orthotopic 
implantations were expected to be more useful to 
develop into metastasis than ectopic ones. Indeed 
limited efficiency of ectopic implants placed in 
non-identical tissues was demonstrated by injecting 
colorectal tumor cells into the lymphoid follicle of the 
cecum [2], carcinoma cells in the kidney or under the 








[4]. In orthoptotic models tumor growth was often too 
fast and required the surgical removal of primary 
tumor to prevent the death of tumorous animals [5]. 
Spontaneous metastatic models have been divided in 
two groups: 1) primary tumor left in the animal till the 
end of the experiment, 2) primary tumor removed to 
detect the growth of the metastasis. The timing of 
primary tumor removal is greatly impacting the re-
sults as the size of the primary tumors is proportional 
to the probability of metastatic development [6]. 
An advantage of the progression of tumors gen-
erated by i.v. administration is that it can be used to 
study the theory of seed and soil. This theory is re-
lated to the clonal expansion of metastasized cells as a 
consequence of modified gene expression in these 
cells, whereas in primary tumors the microenviron-
ment plays a decisive role in tumor progression [7]. 
The seed and soil theory was supported by tumor cell 
lines that consistently disseminated to the liver, ad-
renal gland, bone marrow, but not to the lungs upon 
tail vein injection [8]. Although, the introduction of 
tumor cell lines to the circulatory system might be 
adventageous in the development of metastatic vari-
ants of increasing metastatic potential [9, 10], a serious 
drawback of these models is that they are lacking the 
early steps of the metastatic cascade. 
To provide experimental tools to study metasta-
sis, in vivo animal models turned out to be indispens-
ible, as the development of animal tumors follows the 
same common pathway as those of human tumors. 
Due to the natural multitude and complexity of ani-
mal tumors, it would be impossible to use a single 
model to describe the whole process and necessitates 
a careful selection and application among models. The 
chicken chorioallantois-membrane model is one of the 
oldest metastasis models to study metastasis [11]. The 
advantage of simplicity is contrasted by its suitability 
questioning whether the evolutionary gap between 
birds and mammalians can be bridged by comparing 
their tumors. To study in vivo metastasis, we have 
established mammalian tumor cell lines, among them 
the hepatocarcinoma (He/De), the nephroblastoma 
(Ne/De), the melanoma (Me/De), the myeloblastic 
nephroma (My1/De and My2/De) cell lines. These 
cell lines made it possible: a) to implant exact number 
of tumor cells under the renal capsule of rats by 
placing them on GelasponR gelatin sponge, b) to fol-
low the kinetics and c) the temporal aspects of tumor 
growth. The He/De and Ne/De models led to the 
recognition that tumor growth was accompanied by 
the infiltration of tumor cells to the parathymic lymph 
nodes [12]. This observation raised the question as to 
how tumor cells move from primary tumors to distant 
organs and tissues. 
In this paper we test different types of admin-
istrations of hepatocarcinoma (He/De) tumor cells to 
rats to decide which model would be the most suita-
ble to mimic not only tumor development, but also 
the metastatic spread. Among the administrations 
local tumor formation was induced by subcutanous 
injection, tumor formation in distant locations by in-
travenous injection and syngenic implantation of 
He/De tumor cell line under the kidney capsule 
causing tumor metastasis in the thoracal parathymic 
lymph nodes (PTNs).  
Materials and methods  
Chemicals 
N-nitroso-dimethylamine, collagenases type I, 
hyaluronidase type IV, DNase I, penicillin and strep-
tomycin were purchased from Sigma-Aldrich Co. (St. 
Louis, MO). Growth media and gentamicin were ob-
tained from GIBCO BRL., Life Technologies 
(Gaithersburg, MD). Collagenase Medium consisted 
of RPMI 1640 medium containing 0.1% collagenase 
type I, 0.01% hyaluronidase type IV, 0.01% DNase I, 
100 U/ml penicillin and 100 µg/ml streptomicin. Bo-
vine serum albumin (BSA) was the product of Fer-
mentas International Inc. (Burlington, Canada). Poly-
clonal rabbit anti-rat-GLUT-1, anti-rat-GLUT-3 and 
anti-TGF ß-1 were bought from Abcam Inc. (Cam-
bridge, MA, USA). Texas red-conjugated anti-rabbit 
secondary antibody and Vectashield Hard Set 
mounting medium containing DAPI were from Vec-
tor Laboratories, Ltd. (Peterborough, England). 
Phospate buffered saline (PBS) contained: 140 
mM NaCl, 5 mM KCl, 8 mM Na2HPO4 at pH 7.3. 
Phosphate buffered saline with Tween (PBST) con-
sisted of 0.1% Tween 20, 20 mM Na2HPO4, 115 mM 
NaCl; pH 7.4. The collagenase Solution for perfusion 
contained 30 mg collagenase type IV in 100 ml PBS 
solution. 
Experimental tumor growth in rats 
Hepatocellular tumor formation was induced by 
N-nitrosodimethylamine causing liver, kidney, and 
occasionally lung cancers [13, 14]. Hepatocarcinoma 
(He/De) and nephroblastoma (Ne/De) cell lines were 
established from N-nitrosodimethylamine induced rat 
tumor [15]. Experimental surgery and subrenal im-
plantation of He/De cells were performed as de-
scribed [16, 17]. Autopsy was carried out 6, 12 or 18 
days later after euthanization of rats with urethane 
overdose. To follow tumor growth and spread we 
have used 18FDG positron emission tomography that 
proved to be the standard in metabolic imaging of a) 
enhanced glycolysis, b) utilization of glucose greater 
than background tissue, c) and the detection of pri-
mary and metastatic tumors.  





Male and female inbread Fischer 344 rats were 
kept in a conventional laboratory environment and 
fed on a semi-synthetic diet (Charles-River, Mo, Kft, 
Godollo, Hungary) and tap water ad libitum. All ani-
mals were cared for following the criteria outlined in 
the UK ”Guide for the Care and Use of Laboratory 
Animals” [18], authorized by the Ethical Committee 
for Animal Research, University of Debrecen. 
Establishment of He/De cell line  
The establishment of He/De cell line was de-
scribed earlier [15]. Briefly, freshly resected hepato-
carcinoma (He/De) tissue was minced into small 
(2x2x2 mm) pieces, digested with collagenase medi-
um, filtered through sterile gauze, washed and sus-
pended in RPMI 1640 medium supplemented with 
10% FBS and antibiotics. After overnight incubation at 
37oC in a CO2 incubator, the nonadherent cells were 
discarded and the adherent cells subcultured. After 20 
subcultures the new hepatocarcinoma He/De cell line 
was established.  
Surgical implantation of He/De cells 
 The aim of the experimental surgery (Subrenal 
Capsule Assay - SRCA) was to place He/De cells 
under the capsule of the left kidney and to follow 
metastatic tumor spread. This was performed by 
placing 106 He/De cells in 10 μl saline on GelasponR 
disc. Animals were anesthesized by i.p. administra-
tion of 3mg/100g pentobarbital (Nembutal, Ce-
va-Phylaxia Rt. Budapest, Hungary). The tumor 
cell-containing disc or lymph node was placed under 
the renal capsule of the left kidney. The kidney was 
placed back in the retroperitoneum and the operative 
field was subjected to post-operative treatment. Sub-
cutaneous tumor formation was initiated by the s.c. 
injection of 106 hepatocarcinoma (He/De) cells into 
rats. The third way of tumor induction was the injec-
tion of 106 He/De cell via the femoral vein. Animals 
were euthanized before dissection by an i.p. 300 
mg/kg overdose of Nembutal.  
Measurement of accumulation of glucose 
analog 
Radiotracer synthesis. Chemically known as 
2-deoxy-2-(18F)fluoro-D-glucose, 18FDG is a posi-
tron-emitting radioactive isotope glucose analogue, 
where fluorine-18 is substituted for the normal hy-
droxyl group at the 2' position in the glucose mole-
cule. The glucose analog 18FDG was synthesized and 
labeled with the positron-decaying isotope 18F [19]. 
Radiotracer was synthesized in our Department of 
Nuclear Medicine. 
 MiniPET examinations. For the visualization of 
tumors their high metabolic rate and 18FDG uptake 
were utilized [20-22]. The MiniPET-II camera was 
developed in a joint project by the Department of 
Nuclear medicine, University of Debrecen, by the 
Nuclear Research Institute of the Hungarian Acade-
my of Sciences and by the MEDISO Kft, Budapest, 
Hungary. The MiniPET-II camera consists of 12 de-
tector moduls, 12x35x35 LYSO scintillation crystals of 
1.1 mm resolution with a 5x5 cm field of view. Ex-
perimental animals were given i.v. 7.4±1.2 MBq 
18FDG. After 1 h animals were narcotized with 3 
mg/100 g pentobarbital. PET data were collected for 
10 min from the area of the tumor and the thorax. 
Evaluation was made with the help of the BrainCad 
software. Single frame PET scans were performed for 
20 min using the MiniPET-II small animal PET scan-
ner [23]. 
In vivo uptake of 18FDG glucose analogue. Radio-
tracer uptake was expressed as Standardized Uptake 
Values (SUVs). The estimation of T/M mean comes 
from the ratio of tumor SUV mean versus background 
muscle SUV mean. Ellipsoidal 3-dimensional regions 
of interest (ROI) were manually drawn around the 
edge of the tumor activities by visual inspection using 
the BrainCad software (http:/www.minipetct.hu). 
Assuming a tissue density of 1g/cm3 the standardized 
uptake value (SUV) was calculated as: 
SUV = [ROI activity (Bq/ml)] / [injected activity 
(Bq)/animal weight (g)]     
Immunohistological staining  
The increased uptake of glucose and its 18FDG 
analogue is accounted for by the elevated expression 
of glucose transporters (GLUT 1-12) found in the 
membranes of different tissues and responsible for the 
transport of glucose across the membrane of their cells 
[24]. In accordance with the increased glucose uptake 
in tumor bearing tissues the activities of GLUT 
transporters, especially those of GLUT-1 and GLUT-3 
are significantly higher relative to normal tissues [25]. 
Transforming growth factor beta 1 (TGF-β1) is a se-
creted polypeptide member of cytokines performing 
many cellular functions, including the control of cell 
growth, cell proliferation, cell differentiation and 
apoptosis. The expression of GLUT-1, GLUT-3 and 
TGF-ß1 proteins was detected in control kidney and 
in tumorous kidney 14 days after implantation of 
He/De tumors and in He/De tumor cells.  
Results 
Local tumor formation after s.c. 
administration of He/De cells 
Tumor formation was initiated by the s.c. injec-
tion of 106 hepatocarcinoma (He/De) cells into rats. 




After a lagging period intensive tumor formation was 
observed and 6 days after the injection the tumor be-
came palpable (41±4.2 mm3), and by day 18 it was 
grown to nearly 3 cm3 (Fig. 1A). Further local tumor 
growth would have caused the death of animals. 
Thus, based on ethical considerations after 18 days 
rats were euthanized by over-narcotization.  
In the control experiment rats were given in the 
caudal vein 18FDG (7.4±1.2 MBq) before the s.c. ad-
ministration of tumor cells and 1 h later whole body 
imaging was performed with the MiniPET camera. 
The intensive growth of subcellular hepatocarcinoma 
tumor was detected by glucose metabolism repre-
sented by the 18FDG uptake as SUV values. Six days 
after tumor cell administration the 18FDG SUV mean 
value was 3.8±0.9, and the tumor to mediastinal 
18FDG uptake (T/M) ratio 7.8±0.7. These values in-
creased by day 18 to SUV mean 12.9±2.4, and to a 
T/M mean 24±1.8 (Fig. 1B). Accumulation of the ra-
diopharmacon was observed 18 days after tumor cell 
injection in metabolically active organs including the 
brain (SUV mean: 2.87±0.39), the Harderian gland 
(specialized lacrimal gland found within the eye's 
orbit) (SUV mean: 6.54±1.81), heart muscle (SUV 
mean: 6.72±1.44), in the bone marrow (SUV mean: 
2.29±0.45) and excreted in the urine (SUV mean: 
41.77±3.29) and guts (SUV mean: 1.15±0.21). Chronic 
accumulation that would have indicated infection or 
spontaneous tumor formation was not found.  
 
 
Figure 1. Tumor formation and histological staining after s.c. administration of He/De cells. A. Growth kinetics of local tumor formation (n=3). B. 18FDG-SUV mean values of 
subcutaneously growing primary tumors. For the estimation of T/M mean the ratio of tumor SUV mean versus background muscle SUV mean were used (n=3). C. Visualization 
of tumor formation by 18FDG-MiniPET camera in Fischer 344 rat. a) 18FDG-PET image before administration of He/De cells. Black arrow is pointing to the site of injection of 
He/De cells. b, c, d). Red arrows show the growing tumor at the site of injection after 6, 12 and 18 days. The Standardized Uptake Value (SUV) of 18FDG was used in PET imaging 
as a simple semi-quantitative analysis [26]. SUV represents the ratio of the actual radioactivity concentration found in a selected part of the body at a certain time point, and the 
radioactivity concentration in the hypothetical case of an even distribution of the injected radioactivity across the whole body. D. Histological staining of subcutaneously growing 
hepatocellular He/De carcinoma. Panel a) Hematoxilin-eosin staining of subcutaneously growing hepatocellular He/De carcinoma 18 days after tumor cell implantation. Panel b) 
Immunofluorescent staining of subcutaneously growing hepatocellular He/De carcinoma tumor with GLUT-1 transporter and Texas red background staining. Bar: 50 μm, each. 
 




Static 18FDG-PET exposures were taken at the 
site of tumor formation in the sagittal and coronal 
planes 0, 6, and 12 days following the s.c. injection of 
He/De cells (Fig. 1C/a,b,c). Whole body 18FDG-PET 
imaging was repeated 18 days after tumor cell injec-
tion to visualize potential metastasis formation (Fig. 
1C/d). The analysis of these images has unanoni-
mously shown that subcutaneously growing tumors 
did not project metastases to other sites from the in-
jected area. With the exception of subcutaneous tu-
mor, only physiological amounts of 18FDG were found 
in these animals. This finding was supported by post 
mortem examinations. The conclusion was drawn from 
these experiments that local injection of tumor cells 
generates local tumors, and this type of administra-
tion is unsuitable to study metastasis. 
Histological analysis of subcutaneous tumors 
 Figure 1D/a shows the subcutaneously growing 
hepatocellular He/De carcinoma stained with hema-
toxilin-eosin. Post mortem analysis also included the 
histological expression of GLUT-1 protein that is one 
of the major glucose carriers responsible for trans-
porting 18FDG into cells. High expression of GLUT-1 
transporter in He/De tumor tissue is shown in Fig. 
1D/b. 
Tumor formation after i.v. tumor cell 
administration  
After i.v. administration of tumor cells local tu-
mor formation was seen at the site of the injection. To 
improve the safety of i.v. tumor cell administration 
and to avoid local tumor formation the femoral vein 
was chosen rather than the caudal one. Even in this 
case local tumor formation was observed in four out 
of ten rats at the site of injection caused by the damage 
of the femoral vein where the HeDe cells were in-
jected (Fig. 2A). 
Fischer 344 rats were given through the caudal 
vein 106 He/De cells. At different periods of time after 
injection, 18FDG-PET pictures were taken to follow 
tumor growth. Of the ten rats used in these experi-
ments tumor formation was detected only in six ani-
mals localized in the liver and in the lung. Fig. 2B/a 
shows the distribution of the radiotracer glucose an-
alogue before tumor cell administration. The first 
identifiable tumor appeared in the liver 18±2 days 
after the injection of tumor cells (Fig. 2B/b). The SUV 
mean value for liver tumors was 4.04±0.44, and the 
mean T/M value 8.8±2.08. The tumor formation took 
longer time than after s.c. administration of tumor 
cells. Liver tumor became detectable after 20±3 days 
(Fig. 2B/c). Tumorous lesions were seen in the lung 
(black arrows) and tumor formation in the liver (yel-
low arrows) 22±3 days after tumor cell administration 
(Fig. 2B/d). The SUV mean value for malignant lung 
tumors was 2.4±0.4 and T/M mean 6.7±1.07. The tu-
mors formed after i.v injections were significantly 
smaller relative to those caused by the s.c. application 
of tumor cells. The average volume of the lung tumors 
was 13.5±3.4 mm3 and those of liver tumors 48.0±5.4 
mm3. Tumor formation was not found in other organs 
or tissues. After 24 days of tumor cell administration 
liver injury was confirmed histologically by the tu-
morous infiltration of He/De cells (Fig. 2C/a). Im-
munofluorescent staining confirmed the overexpres-




Figure 2. Tumor formation in rat upon injecting He/De cells in the femoral vein. A. 
Local tumor formation. a) Tumor formation seen at the site of femoral vein injection. 
b) Surgical visualization of local tumor formation at the site of i.v. injection. Black 
arrows indicate the He/De primary tumor at the left hind leg. The tip of the blue 
needle shows the site of injection. B. 18FDG-PET photographs taken after i.v. injection 
in Fischer 344 rats and post mortem examinations. a) Control: 18FDG-PET image 
before the injection of He/De cells. b) 18FDG-PET image 18 days and c) 20 days after 
intravenal application of He/De tumor cells. d) Tumorous lesions in the lung (black 
arrows), tumor formation in the liver (yellow arrows) 24 days after tumor cell 
administration. C. He/De tumor cells infiltrated in the liver 24 days after He/De i.v. 
administration. a) Hematoxilin-eosin staining. Yellow arrow points to the healthy liver 
tissue, black arrows are directed towards the invasion of tumor cells with large 
disruptions outside and inside the tumor. b) Visualization GLUT-1 transporters in 
liver tumor stained with Texas red. Bars: 50 μm, each. 
 




Subrenal Capsule Assay (SRCA)  
Experimental surgery was performed to place 
gelatin disc (GelasponR) containing He/De tumor 
cells (106) under the capsule of the left kidney of rats 
(Fig. 3A). The implantation of tumor cells under the 
subrenal capsule (Fig. 3A/a-c) induced an intensive 
growth of He/De cells observed as primary tumor at 
the site of insertion (Fig. 3A/d). 
Intensive primary tumor growth was seen after 
the implantation of 106 He/De cells under the sub-
renal capsule of rats (abdominal parts in Fig. 3B/a-e). 
Accumulation of 18FDG in the primary tumor under 
the left kidney was measurable with the MiniPETII 
camera 3 days after tumor cell implantation (1.7±0.5 
SUV mean, 4.9±0.7 T/M mean). Glucose metabolism 
of the primary tumor increased on day 14 to a SUV 
mean of 5.7±1.3 and T/M mean 13.8±2.1. After day 14 
only the primary tumor and the thoracal lymph nodes 
showed further 18FDG accumulation. The primary 
tumor became palpable 7 days after He/De cell 
transplantation (38±3.4 mm3), and its abdominal dis-
tribution exceeded 2000 mm3 after 18 days.  
18FDG-MiniPET examinations also provided in-
formation with respect to the spread of the He/De 
tumor cells from the site of the retroperitoneal pri-
mary tumor of the kidney to the thoracal site of the 
first metastasis (thoracal parts in Fig. 3B/a-e). The first 
detectable metastasis was seen in the thorax (Fig. 
3B/a, b, c). The metastatic infiltration of He/De cells 
to the thoracal cavity became detectable 7±1 days after 
tumor cell implantation (Fig. 3B/c).  
The site of metastasis was identified after post 
mortem surgery as the parathymic lymph node (Fig. 
4). The weight of the thymus did not change sug-
gesting that it was not involved in the metastatic 
spread of He/De cells (Fig. 4A/a). The weight of par-
athymic lymph nodes increased enormously from the 
control 23.5±2.5 mg to 1.5-2.0 g of the tumor bearing 
PTNs (Fig. 4A/b). The histological pictures of control 
and tumorous PTNs differed significantly. Contrary 
to the relatively homogeneous distribution of cells in 
control PTN (Fig. 4B), the tumorous PTN contained 
disruptions with infiltrations of red blood cell (Fig. 
4C). 
Metastatic spread from primary tumor to PTN 
The control experiment by taking whole body 
18FDG–PET images before the implantation of He/De 
cells served the exclusion of chronic inflammation and 
spontaneous tumor formation that could have led to 
the accumulation of the radiopharmakon. Physiolog-
ical accumulation of 18FDG was observed in the brain 
(SUV mean: 2.37±0.25), Harderian gland (SUV mean: 
5.98±1.54), heart muscle (SUV mean: 6.82±1.34), unine 
(SUV mean: 39.76±4.25), guts (SUV mean: 1.28±0.31), 
and in the bone marrow (SUV mean: 1.99±0.33). 
 
 
Figure 3 Tumor growth after subrenal implantatation of He/De cells. A. During the experimental surgery technique known as Subrenal Capsule Assay (SRCA): a) the left kidney 
of the rat was exposed, b) GelaspongeR disc containing 106 He/De cells was placed under the capsule of kidney, c) kidney containing the implanted tumor cells was placed back 
in the retroperitoneum and the operative field was subjected to post-operative treatment, d) primary tumor formation 7 days after He/De cell implantation. B. Sagittal images of 
18FDG-PET before and after implantation of He/De cells under the capsule of left kidney of rats. a) miniPET image before He/De cell implantation. PET images 3 days (b), 7days 
(c), 14 days (d) and 18 days (e) after implantation. White arrows indicate the heart, black arrows the primary tumor in kidney, red arrows metastases in parathymic lymph nodes 
(PTNs). 





Figure 4. Metastasis in parathymic lymph nodes upon subrenal implantation of 
He/De cells. A) Metastatic infiltration in the thoracal parathymic lymph nodes (PTN) 
two weeks after implantation. a) Lack of tumor formation in the thymus. b) Enlarged 
tumorous PTN. B. Hematoxilin staining of control PTN. C) Hematoxilin staining of 
tumor bearing PTN. Bars, 500 µm each. 
 
Figure 5. summarizes the SUV mean and T/M 
mean values of the primary tumor at different time 
points after implantation (Fig. 5A) and the metastatic 
tumor in PTNs (Fig. 5B). These values indicate that the 
rate of glucose metabolism is proportional to tumor 
growth. Highest SUV mean and T/M mean values 
were registered 18±1 days after He/De cell implanta-
tion both in the primary and in the metastatic PTN 
tumors. Due to the enormous size of the primary tu-
mors and the metastatic impact on abdominal organs, 
further suffering of animals was terminated by eu-
thanization. 
The formation of primary and metastatic tumors 
was supported by histological examinations in kidney 
and in PTNs (Fig. 6). Immunofluorescent images of 
tumor infiltrated areas relative to control tissues re-
vealed high GLUT-1 (Fig. 6 a-d), GLUT-3 (Fig. 6 e-h) 
and TGF-ß1 protein (Fig. 6 i-l) expressions. Immuno-
histochemical staining helped to distinguish not only 
between normal and cancerous cell growth, but also 





Figure 5. Tumor formation at the primary site of implantation and metastasis in PTNs. A) 18FDG-SUV and T/M values of the primary tumor growth under the capsule of the 
kidney. B) Metastasis in thoracal parathymic lymph nodes (PTNs). T/M mean is the ratio of tumor SUV mean versus background muscle SUV mean. Values are averages of three 
independent experiments. C) Sagittal 18FDG-MiniPET II image picture of control rat after i.v. administration of 18FDG and its appearance in the heart as the major blood containing 
organ. D) Sagittal 18FDG-MiniPET II image of rat two weeks after subrenal implantation of He/De cells. White arrow indicates the location of the primary kidney tumor, red arrow 
points to PTNs. 
 





Figure 6. Immunohistochemical staining of control kidney and hepatocellular carcinoma developed two weeks after subrenal implantation of He/De cells. Primary and metastatic 
tumors were induced by the subrenal implantation of either He/De tumor slices, or He/De tumor cells. Tumor formation after implantation was also detected in parathymic 
lymph nodes. Texas red staining of GLUT-1 (a-d), and GLUT-3 (e-h) transporters and TGF-ß1 protein (i-l) were performed in control kidney, in He/De tumor, He/De cell 
infiltrated kidney and in metastatic PTN tissues. Bars: 50µm, each. 
 
Discussion 
The significantly higher metabolic activity of 
tumor cells relative to normal cells served as a basis to 
investigate the distribution of the radiotracer glucose 
analogue. 18FDG has been initially used to measure 
the glucose metabolism in mice by gas chromatog-
raphy and radioassay [28]. The use of 18FDG has been 
extended to mimic the elevated glucose uptake in 
tumor bearing animals. Results related to human ma-
lignant transformations described elevated 18FDG 
uptake in brain and liver tumors [27]. Conforming to 
these observations we have found that in tumor cells 
the 18FDG uptake was significantly higher than in 
control cells, and corresponded to the overexpression 
of cell surface glucose transporters. The relationship 
between 18FDG uptake and facilitative glucose trans-
porters was proven [28], and clarified that of the 12 
known GLUT transporters GLUT-1 and GLUT-3 are 
preferentially used in 18FDG uptake [29]. That 
GLUT-1 transporter secures the ubiquitous basic 
glucose level and storage has been confirmed in 
erythrocytes, cells of endometrium and fetal tissues 
[30-32]. In tumor cells the expression of GLUT-1 
transporter was significantly higher than the levels of 
other GLUT transporters [28]. Irrespective of the ap-
plied tumor models our immunohistological exami-
nations confirmed higher GLUT-1 protein expression 
in various tumor cells.  
Our earlier experiments have shown that tumor 
cells of epithelial (He/De) or mesodermic nephro-
blastoma (Ne/De) origin implanted under the capsule 
of the kidney of rats generated metastasis in the par-
athymic lymph nodes [33]. Similarly, myeloid 
My2/De leukemia tumor cells implanted subrenally 
followed the same metastatic route and accumulated 
in parathymic lymph nodes [34]. To clarify how tu-
mor progression can lead to metastatic spread, three 
animal models have been tested in our experiments: 
1. During the subcutaneous introduction of tu-
mor cells rats have been subjected to s.c. administra-
tion of hepatocarcinoma (He/De) cells. Contrary to 
the fast growth of the primary tumor at the site of 
injection, none of the animals has shown transmissi-
bility of tumor cells from the local tumor to other or-
gans of the animals. Contrary to other s.c. tumor 
models that have been applied successfully to gener-
ate metastasis [35], in our experiments subcutane-
ously induced local tumors did not project metastases 
to distant places. Consequently, we did not find s.c. 




models suitable to study metastasis.  
2. Intravenous application of tumor cells. This is 
the most frequently applied method to introduce tu-
mor cells into experimental animals. Other forms of 
administration to the circulatory system are in-
tra-arterial or intracardial injections. The generation of 
liver metastasis is a relatively reliable method, when 
the tumor cell suspension is injected directly into the 
spleen or in the portal vein. During this procedure 
tumor cells are injected immediately into the cardio-
vascular system. This application faces the dilemma 
of important early steps in the metastatic process 
could be missing. A further danger of injecting ag-
gregated tumor cells in the middle caudal vein of ro-
dents carrying blood from the lower part of the body 
is that tumor cells are deposited in the neighboring 
capillaries. The tail vein leads directly to the inferior 
vena cava and the right atrium. From the right ventri-
cle of the heart the pulmonary circulation carries tu-
mor cells to the capillaries of lung where these ag-
gregated cells can cause microemboli and initiate 
metastases. Even more unpredictable is the injection 
of tumor cells directly into the heart, as metastases can 
spread to different locations including the bones.  
Based on our observations i.v. injections often 
result in local tumor formation at the site of injection 
or if this can be evoided, it is unpredicatable where 
tumor cells will adhere if there will be tumor for-
mation at all. Only three of the five rats that have been 
given He/De tumor cells i.v. developed metastasis in 
the lung and liver. Another notable difference relative 
to the s.c. induced primary tumors was the low speed 
of tumor growth and smaller tumor size. The accu-
mulation and growth of tumor cells in the liver can be 
explained by the extraction of intravenously injected 
colloidal particles, including tumor cells. In conform-
ity with tumor growth in the liver we have found 
earlier that i.v. added 118mIn colloidal particles were 
extracted by the Kuffer cells of the MALT, formerly 
referred to as reticuloendothelial system [36]. The 
distribution of colloidal particles in liver (98%), spleen 
(1.5%) and lung (0.2%) of rats proved that the primary 
sites of colloide extraction were not the primary 
lymphoid (bone marrow, thymus), but the secondary 
lymphoid organs, primarily the liver and the spleen. 
The extraction of colloidal particles was independent 
of the size within the colloidal range [36]. The ap-
pearance of tumors in the lung upon i.v. administra-
tion of tumor cells can be explained by the formation 
of particles larger than the colloidal size (>10 μm). 
Macroaggregate formation, such as trombi causes 
microembolization in microvessels between arterioles 
and venules [37]. 113mIn–Fe(OH)3 macroaggregates 
generated microembolization in the lung of rats [41]. 
The heterogeneity of 113mIn–Fe(OH)3 macroaggregates 
containing larger than 10 μm particles made these 
preparations unsuitable for lung scintigraphy when 
injected i.v. to rats, causing temporary occlusions in 
vessels of vital organs such as the heart and lung. To 
avoid microembolization and tumor metastasis in the 
lung, intravenously administered tumor cells should 
not exceed the colloidal size range. There was another 
disturbing factor during the i.v. adminstration of tu-
mor cells, namely local tumor formation at the site of 
injection caused by the damage of the caudal vein. 
Due to these uncertaintenties i.v. administration of 
tumor cells does not provide a reliable metastatic tu-
mor model. 
3. Tumor cells implanted under the subrenal 
capsule of rats induced rapid local tumor growth de-
tactable three days later and projected metastasis to 
distant lymph nodes in all animals tested. The first 
metastasis appeared in each case around day 7 in the 
paratymical lymph nodes, in conformity with our 
earlier observations [12, 15, 39]. The uptake of 18FDG 
correlated to the rate of tumor growth. The accumu-
lation of 18FDG could be reliably followed by a Mini-
PET camera. 18FDG-PET preclinical examinations 
combined with other tests could improve diagnostic 
means to follow, understand and prevent metastasis. 
There is one more question that needs explana-
tion, namely how tumor cells released from the pri-
mary tumor to the peritoneal space enter the thoracal, 
primarily parathymic lymph nodes. Other authors 
have found that beside parathymic lymph nodes the 
i.p. administered India ink appeared in mediastinal 
lymph nodes [40]. We have mimicked the release of 
tumor cells from the primary tumor either by im-
planting ink particles under the capsule of the kidney 
or injecting the ink directly into the peritoneum. Ir-
respective of the subrenal implantation or direct in-
jection of ink, these particles deposited not only in 
abdominal organs, but also in the thoracal, preferen-
tially in the parathymic lymph nodes. When rat leu-
kemia (My1/De) cells were injected i.p. they passed 
across the diaphragm and similarly to colloidal car-
bon particles deposited preferentially in the para-
thymic lymphatics [41] confirming the notion of 
lymphatic rather than hematogen dissemination of 
abdominal tumors.  
Based on the”soil and seed” hypothesis it was 
reasoned that cancers are not randomly distributed, 
tumors grow only in those organs that are predis-
posed to secondary cancers [7, 42]. The theory of 
hematogen spread of metastasis suggests that tumor 
cells cross the barrier of the tumor capsule, enter the 
circulation and exit through the endothelial cells of 
the blood vessels [43]. After adaptation to the micro-
environment cancer cells start to divide [44]. Recently 
the lymphoid-hematogen aspect of metastasis for-




mation prevails, but the spread of broken away tumor 
cells from the peritoneal cavity to the thoracic lymph 
nodes is more in the favor of a lymphatic drainage [45, 
46].  
To summarize our observations, by the admin-
istration of exact number of tumor cells we could fol-
low the temporal aspects of the tumor development in 
rats. The rat kidney capsule-PTN complex traces tu-
mor progression from the place of implantation to the 
site of metastasis. This model is expected to provide 
further explanations regarding the peritoneal, retro-
peritoneal and thoracal metastatic tumor develop-
ment. The fact that other small colloidal particles (In-
dia ink) also move from the abdominal to the thoracal 
cavity is a clear indication of a general pathway that 
foreign particles follow including tumor cells. The 
advantage and utilization of our metastatic model can 
be summarized as:  
1. Exact number of tumor cells obtained from 
established tumor cell lines can be implanted under 
the kidney or liver of rats. Rat rather than murine 
model was used as in mice, the parathymic lymph 
nodes are inside the thymic capsule and can be re-
moved only with the thymus, whereas in rats these 
nodes, regularly three or four on each side lie on the 
capsule and can be isolated as separate glands [47]. 
2. The temporal development of primary tumor 
growth and the secondary tumor formation (metasta-
sis) can be planned and followed more reliably than 
by implanting tumor slices.  
2. Our metastatic rat tumor model clarified that 
due to delayed angiogenesis, the inner part of primary 
tumor necrotized. The arterial blood pressure and the 
lack of venous backflow channeled blood and tumor 
cells to the interstitial fluid [39, 45, 46].  
3. Elevated interstitial pressure at the outer part 
of the primary tumor caused disruptions and released 
blood and tumor cells into the neighboring tissues 
[15]. 
4. The broken away blood cells along with the 
released tumor cells drained from the kidney tumor to 
the retroperitoneal space and from the liver to the 
peritoneal space and further through the diaphragm 
to the thoracal lymphatic vessels [48, 49], with para-
thymic lymph nodes being the sentinel lymph nodes 
[12, 15, 39].  
5. This model supports the notion that similar to 
bacteria, cancer cells cooperatively develop complex 
communities (primary tumors) with cell differentia-
tion and distribution of tasks [48, 49]. 
Our experiments are in conformity with the idea 
that the disruption of the tumor capsule and its asso-
ciated physical barriers are pre-requisites for tumor 
cell invasion or metastasis from the primary tumor 
[50]. The degradation or disruption of the tumor 
capsule and the invasion from in situ primary tumors 
to metastatic cancer is likely to be supported by pro-
teolytic enzymes produced by tumor cells [51-53] and 
by tumor-infiltrating immune cells [53]. Delayed an-
giogenesis and vascular movement probably also 
contribute to the disruption of the capsule of the pri-
mary tumor. Released tumor cells enter neighboring 
tissues and body fluids and initiate the formation of 
micrometastases of lymphatic origin rather than by 
the hematogeneous dissemination of metastases. 
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